A Phase I, Open-label, Multicenter Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Volitinib in Patients With Advanced Solid Tumors

Trial Profile

A Phase I, Open-label, Multicenter Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Volitinib in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs Savolitinib (Primary)
  • Indications Gastric cancer; Lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 01 Aug 2016 According to Chi-Med and AstraZeneca media release, first patient was dosed in Q2 2013 (in the entire advanced solid tumors cohort).
    • 01 Aug 2016 According to Chi-Med and AstraZeneca media release, first patient dosed in Advanced gastric cancer cohort with third line MET overexpression patients during Q4 2014 and last patient commenced dosing during Q4 2015.
    • 01 Aug 2016 According to Chi-Med and AstraZeneca media release, first patient dosed in Advanced gastric cancer cohort with all lines MET gene amplified patients during Q4 2014 and last patient will commence dosing during Q4 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top